Toll-like receptor agonist formulations and their use

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/55 (2006.01) A61P 17/00 (2006.01) A61P 31/00 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2732437

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.

La présente invention porte d'une manière générale sur des formulations stables d'un agoniste de TLR, de préférence, un agoniste de TLR7 ou de TLR8, pour une utilisation dans le traitement du cancer, de préférence, de tumeurs solides et de lymphômes. La présente invention porte spécifiquement sur des formulations stables allant jusqu'à 50 mg/ml d'un agoniste de TLR qui comprend une cyclodextrine.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Toll-like receptor agonist formulations and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Toll-like receptor agonist formulations and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Toll-like receptor agonist formulations and their use will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1341809

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.